The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for publication of novel and innovative research
from areas of pharmaceutical technology, drug delivery systems, controlled release systems, drug targeting, physical pharmacy, biopharmaceutics,
drug development, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, GMP, regulatory aspects, pharmaceutical
packaging, and phytochemistry.
The pharmaceutical biotechnology section provides a forum for the publication of papers on scientific,
developmental, regulatory and manufacturing issues concerning the development of biopharmaceuticals, uniquely combining expert contributions
and opinions of authors from the fields of pharmaceutics and biotechnology. This scope encompasses modern biopharmaceuticals
(e.g., proteins
and nucleic acids), biosimilars/biogenerics as well as 'traditional' products such as antibiotics.
The following types of papers
are considered by the Editors: Research Papers, Review Articles, and Notes.
Papers must be written in English. Organization of the
manuscript must follow the style of the Journal. For more detailed information on artwork instructions CLICK HERE.
"THE RULES OF 3"
The Editors and Editorial board have developed the "Rules of
3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and
reviewing at work. The rules are also used as guidelines for the peer review of manuscripts.
CLICK HERE
to view the "Rules of 3".
Full length papers are recommended not to exceed a total
of 20 double-spaced, font size 12, typewritten pages, excluding references, tables, figure legends, and figures, and should include Title,
Abstract, Methods and Materials, Results, Discussion, Conclusions, Acknowledgments and References. It is also recommended that the total
number of tables and figures does not exceed 8. Authors can deposit additional data as (online) supplementary data. Instructions can
be found at http://www.elsevier.com/artworkinstructions.
Review of manuscripts
Upon receipt, a manuscript
will be peer-reviewed. The reviewers' relevant comments and the editor's decision will be communicated to the authors.
Research
papers
TITLE
It should be carefully chosen to provide precise information about the contents and include important
keywords. The title should be followed by the full name(s) of the author(s) and by his (her, their) affiliation(s). Different affiliations
should be indicated by suitable superscripts.
To ensure identification of the corresponding author, please indicate full name, full
postal address, e-mail address, phone and facsimile on the cover of the manuscript.
KEYWORDS
Indicate 5 to 10 English keywords.
They should be carefully selected in order to improve accessibility of scientific information in the manuscript. Keywords commonly used
in international abstracting services will be preferred.
ABSTRACT
It should contain a brief and clear description of the
aim of the paper, its principal results and major conclusions (100--200 words). The abstract should include all keywords pertinent to
the subject.
RESEARCH PAPERS
Should contain the following sections: Introduction, Theoretical Development (if applicable),
Materials and Methods, Results, Discussion (or Results and Discussion) and References. For purely theoretical papers, appropriate sections
may be selected.
INTRODUCTION
It should define the purpose of the research and reveal its connections with the principal
work of other authors in the field.
MATERIALS AND METHODS
It should include materials, standard techniques and procedures
relevant to the study. Published procedures and techniques should be cited unless significant modifications are involved. Exact specification
of relevant materials and equipment must be given. Chemical terms must conform with IUPAC rules. Trademarks of commercial products must
be labelled using a superscripted '(r)'. Names of products and equipment mentioned in the Materials and Methods section must be accompanied
by the name of the manufacturer or distributor, location and state or country. This information must be stated in parentheses in the
text, and not as a footnote. Any potential hazards connected with materials and procedures must be mentioned. A precise and detailed
description should be given of those steps which are of vital importance in carrying out any repetition of the work. The Declarations
of Helsinki and Tokyo for humans, and the European Community guidelines as accepted principles for the use of experimental animals, must
be adhered to. Therefore, EJPB will only consider manuscripts that describe experiments that have been carried out under approval
of an institutional or local ethics committee. Authors must state in the manuscript that the protocol complies with the particular
recommendation and that approval of their protocols was obtained.
Equations must be part of the text and consecutively numbered
on the right hand side using numbers in parentheses. References to equations in the text are also to be made with parentheses, e.g. using
Eq. (3), etc.
Organic formulas, both in figures and in the text, should be numbered in boldface arabic numerals.
SI units
must be used throughout.
RESULTS
Results may be presented in tables, figures or schemes which must be referred to in the
accompanying text, using appropriate numbering, e.g. Fig. 1, Table 2.
DISCUSSION
It should focus on the interpretation of
the results. It might be appropriate to combine RESULTS AND DISCUSSION in one section. If necessary at all, use CONCLUSIONS only to illustrate
the general implication of the results and do not summarize the previous text.
TABLES
Tables must be presented on separate
sheets in consecutive order using Arabic numerals. The table headings must include a descriptive title and additional information to
make the table self-explanatory. Some information may be given by using lower-case letter designations referring to footnotes at the
bottom of the table. Indicate SI units of measure in parentheses.
FIGURES
Figures must be presented on separate sheets in
consecutive order using Arabic numerals. Each figure should be provided with an instructive title and explanatory information. The legend
should be typed separately from the figures. To ensure identification of the figures, indicate figure number and name of author using
soft pencil. Submit original drawings in black ink on good quality white paper. High-contrast photographs are equally acceptable. One
original set is required with the submission. Numbering and lettering of figures should be carefully accepted in order to ensure readability
after photographic reduction of the figure. Use only standard symbols to mark datapoints. Explanation of curves and symbols should be
in the legend rather than part of the drawing, unless this is detrimental to clarity. Indicate SI units of measure in parentheses.
Colour illustrations should be submitted as original photographs, high-quality computer prints or transparancies, close to the size expected
in publication or as 35 mm slides. Polaroid colour prints are not suitable. If, together with your accepted article, you
submit usable colour figures then Elsevier will ensure , at no additional charge, that these figures will appear in colour on the web
(e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version.
For colour reproduction in print, you will receive information regarding the total cost from Elsevier after receipt of your accepted
article. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications which can arise by converting colour figures to 'grey scale'(for the printed
version should you not opt for colour in print) please submit in addition usable black and white prints corresponding to all the colour
illustrations.
A limited number of colour photographs are accepted free of charge with prior permission from the Editor-in-Chief.
Colour photographs above this number will only be reproduced at the expense of the author(s). The 2006 price for colour figures is 285
Euro for the first page and 191 Euro for subsequent pages.
CITATIONS
Citations of literature in the text must be presented
in numerical order. Type numbers in parentheses and do not use superscripts. If names of authors are part of the text, use last names
only.
USE OF DIGITAL OBJECT IDENTIFIER (DOI)
The digital object identifier (DOI) may be used to cite and link to electronic
documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial
electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document particularly "Articles
in press" because they have not yet received their full bibliographic information.
The correct format for citing DOI is shown as follows:
doi:10.1016/j.ejpb.2004.10.006
REFERENCES
References must be arranged as follows:
[1] A.-L. Cornaz, P. Buri, Nasal mucosa
as an absorption barrier, Eur. J. Pharm. Biopharm. 40 (1994) 261--270.
[5] C. Lanczos, Applied Analysis, Prentice-Hall, Englewood Cliffs,
NJ, 1967, pp. 272--280.
[10] D.M. Barends, Stability of active ingredients, in: H. Müller, W.H. Oeser (Eds.), Drug Master Files,
Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany, 1992, pp. 121--128.
[14] E.A. Balazs, Ultrapure hyaluronic acid and
the use thereof, U.S. Patent 4,141,973 (1979).
The system used by Chemical Abstracts (Chemical Abstracts Service Source Index) must
be followed for the abbreviations of journals. Reference (4) is for patents, including the status, international country code, number
of patent and year. Articles in Special Issues: Please ensure that the words 'this issue' are added (in the list
and text) to any references to other articles in this Special Issue.
ACKNOWLEDGEMENTS
Acknowledgements of financial support,
gifts, technical help or other assistance may be given in an unnumbered paragraph under this heading preceding the references.
Notes
The
research and technical notes section of the journal (maximum 2500 words) is open to interesting results worthy of publication without
requiring extensive introduction and discussion. This section should contain the following subheadings: Abstract, Introduction, Materials
and Methods, Results and Discussion (combined). No more than 10 references should be used. Tables, figures and references are to be arranged
according to research papers. Brevity of presentation is essential for this section. Five to 10 keywords should be provided.
Review
articles
The organization and subdivision of review articles can be arranged at the author's discretion. Tables, figures and references
are to be arranged according to research papers. An abstract, table of contents, and keywords are requested.
Copyright guidelines
for authors
All authors must sign the "Transfer of Copyright" agreement before the article can be published. The transfer agreement
enables Elsevier to protect the copyrighted material for the authors, but does not relinquish the author's proprietary rights. The copyright
transfer covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform,
or any other reproductions of similar nature and translations, and includes the right to adapt the article for use in conjunction with
computer systems and programs, including reproduction of publication in machine-readable form and incorporation into retrieval systems.
Transfer of copyright agreement forms will be sent to the corresponding author following acceptance of the manuscript.
If excerpts
from other copyrighted works are included, the Author(s) must obtain written permission from the copyright owners and credit the source(s)
in the article. Elsevier has preprinted forms for use by Authors in these cases: Contact Elsevier's Rights Department, Oxford, UK: phone
(+44) 1865 843830, fax (+44) 1865 853333, e-mail permissions@elsevier.com Requests may also be completed on-line via the
Elsevier homepage (http://www.elsevier.com/locate/permissions )
Retained authors' rights
As an author
you (or your employer or institution) may do the following: • make copies (print or electronic) of the article for your own
personal use, including for your own classroom teaching use • make copies and distribute such copies (including through e-mail)
of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g., via an
e-mail list or list server) • post a pre-print version of the article on Internet websites including electronic pre-print servers,
and to retain indefinitely such version on such servers or sites • post a revised personal version of the final text of the
article (to reflect changes made in the peer review and editing process) on your personal or institutional website or server, with a
link to the journal homepage (on http://www.elsevier.com) • present the article at a meeting or conference and
to distribute copies of the article to the delegates attending such a meeting • for your employer, if the article is a 'work
for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company
use (e.g., training) • retain patent and trademark rights and rights to any processes or procedure described in the article
• include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially)
• use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent
to publication of your article in the journal) • prepare other derivative works, to extend the article into book-length form,
or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal
Correcting proofs and reprints
Elsevier will send PDF proofs to authors by e-mail for correction. If an author is unable
to handle this process, regular print proofs will be sent. Elsevier will do everything possible to get the article corrected and published
as quickly and accurately as possible. Therefore, it is important to ensure that all corrections are sent back in one communication.
Subsequent corrections will not be possible. Only typesetting errors may be corrected; no changes in, or additions to, the accepted manuscript
will be allowed. Proofs should be returned to Elsevier within 48 hours.
EJPB has no page charges. Fifty offprints of each
paper will be supplied free of charge to the corresponding author. Additional offprints can be ordered at prices shown on the offprint
order form that accompanies the copyright form.
Language Polishing
For authors, who require information about language
editing and copyediting services pre- and post-submission, please visit http://www.elsevier.com/wps/find/authorshome.authors/languagepolishing
or contact authorsupport@elsevier.com for more information. Please note Elsevier neither endorses nor takes responsibility
for any products, goods or services offered by outside vendors through our services or in any advertising. For more information please
refer to our Terms & Conditions.
US National Institutes of Health (NIH) voluntary posting ("Public Access") policy
Elsevier facilitates author posting
in connection with the voluntary posting request of the NIH (referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm)
by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, after formal publication. Upon
notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com)
that your work has received NIH funding (with the NIH award number, as well as the name and e-mail address of the Prime Investigator)
and that you intend to respond to the NIH request. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version
of your manuscript that will include peer-review comments, for posting 12 months after the formal publication date. This will ensure
that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed
Central, and any such posting is prohibited. Individual modifications to this general policy may apply to some Elsevier journals and
its society publishing partners.
Author enquiries
All questions arising after acceptance of a manuscript by the Editor,
especially those relating to proofs, publication and reprints, should be directed to the Publisher.
Elsevier Ireland Ltd
Brookvale
Plaza
East Park
Shannon, Co. Clare
Ireland
Tel: +353-61-709600
Fax: +353-61-709100
E-mail:authorsupport@elsevier.com
For enquiries relating to the submission of articles (including electronic submission where available) please visit this journal's
homepage at http://www.elsevier.com/journals. From here you can also track accepted articles (http://www.elsevier.com/trackarticle)
and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed artwork guidelines, copyright information,
frequently asked questions and more.
Contact details for questions arising after acceptance of an article, especially those relating
to proofs, are provided after registration of an article for publication.
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability,
negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.
Because of the rapid advances made in the medical sciences, independent verification of diagnoses and drug dosages should be made.
